Home About VISION VISION Important Notice This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. I Agree At Astellas, we are relentless in our pursuit of scientific progress and in identifying unmet medical needs by monitoring the changes in healthcare from multiple perspectives. We are committed to the realization of greater VALUE by patients and healthcare systems around the world. We achieve this by leveraging our strengths to create innovative new drugs and to find solutions that drive patient access to healthcare and better outcomes. Our Common Definition of VALUE is the Foundation to Realize Our VISION For Astellas to realize its VISION, we work with a “Common Definition of VALUE” (see graphic below) to clearly communicate and share our aspirations with diverse stakeholders. *Adapted from “What Is Value in HealthCare?” Porter, M.E. (2010). New England Journal of Medicine With “outcomes that matter to patients,” Astellas is committed beyond the safety and efficacy of treatments. We seek to understand and optimize our products, and their subsequent use, to maximize improvements in quality of life (QOL) and to minimize the burdens they create. For "costs to the healthcare system of delivering those outcomes," we are looking at the individual costs borne by the patient, the healthcare costs borne by insurance companies and public institutions, as well as the indirect costs and burdens imposed on the patient's family and care givers. For example, if a drug proves effective in treating a disease that has conventionally required surgery, the outcome for the patient will be significant. It will not only lessen the physical burden on the patient, but also the mental and lifestyle burdens generally experienced by patients. These benefits are not limited to the patients alone. They will ripple out across society, from the patient's families and friends to medical institutions as a whole. With lower hospitalizations and surgeries, these institutions can care for a higher number of patients. Therefore, reducing the denominator in our Common Definition of VALUE equation can affect a positive change across society. We believe that by placing this concept at the core of our business and adapting it to all divisions and regions, Astellas will be able to make a greater contribution to healthcare. Corporate Strategic Plan 2021 (CSP2021) is based on this "VALUE” equation, with an overall aim to increase VALUE for patients and realize our VISION. Corporate Strategic Plan 2021 (CSP2021) The CSP2021 lays out multiple strategies that further develop our existing foundations and builds toward sustainable growth for the next five years, leading to the end of FY2025. Click here to read more about CSP2021. Kenji Yasukawa, Ph.D., President and CEO, explains his motivation to successfully execute CSP2021 and deliver the strategies by utilizing Astellas’ strengths. Click here to read more about the story behind CSP2021. ABOUT From the CEO Philosophy VISION Corporate Information Main Products Global Network History Board of Directors Top Management Corporate Governance Policies & Position Statements Ethics & Compliance Medical Care & Pharmaceutical Information Bottom footer menu SITE MAP PRIVACY POLICY ACCESSIBILITY TERMS OF USE CONTACT US DISASTER INFORMATION FOR EMPLOYEES © Astellas Pharma Inc.